<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696475</url>
  </required_header>
  <id_info>
    <org_study_id>PC007</org_study_id>
    <nct_id>NCT00696475</nct_id>
  </id_info>
  <brief_title>Diazoxide Choline in Hypertriglyceridemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentialis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Essentialis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertriglyceridemia affects 30% of the population in the US. Very high level of
      triglycerides is a known risk factor for pancreatitis. In addition, studies have shown that
      hypertriglyceridemia is an independent risk factor for cardiovascular disease.

      Diazoxide is a KATP channel opener. It has been approved by the FDA as an oral suspension for
      the treatment of hyperinsulinemic hypoglycemic conditions and as an IV solution for malignant
      hypertension. Preclinical and clinical studies suggest that diazoxide can be a potential
      therapeutic agent for hypertriglyceridemia.

      Diazoxide choline is a novel, highly crystalline proprietary salt of diazoxide, which has
      been formulated as a controlled-release tablet suitable for once per day dosing. This current
      study is designed to assess the effect of diazoxide choline on triglycerides in subjects with
      baseline hypertriglyceridemia. In addition, the effects on other lipid parameters, glucose
      and insulin, body weight as well as the safety and tolerability of diazoxide choline will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect on triglycerides of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect on other lipid parameters (LDL, HDL, VLDL, and non-HDL cholesterol), insulin, glucose and weight of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of repeated doses of Diazoxide Choline Controlled-Release Tablet over a period of 56 days in hypertriglyceridemic subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diazoxide equivalent dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diazoxide equivalent dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diazoxide equivalent dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide choline</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide choline</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide choline</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  triglycerides ≥ 250 mg/dL and &lt; 600 mg/dL

          -  BMI between 18.5 and 45

          -  Signed informed consent form

        Exclusion Criteria:

          -  Fasting glucose ≥ 126 mg/dL

          -  Glycosylated hemoglobin (HbA1c) &gt; 6.5%

          -  LDL cholesterol &gt; 190 mg/dL

          -  Known history of type I and II DM

          -  Known history of type I and III hyperlipidemia

          -  Weight change &gt; 3 kg between screening and baseline visits

          -  Pregnancy or intention to become pregnant

          -  Presence of significant underlying conditions that may interfere with the assessments
             of the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Bays, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L-MARC Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Forker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Lipid and Diabetes Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Huffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meridien Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Koren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacksonville Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Lewin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Littlejohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Medical Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Morin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriCities Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eli Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sterling Research Group, Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evan Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic and Atherosclerosis Research Center (MARC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Toth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Institute for Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frederick C. Smith Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glibert Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International/Cetero Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Research International/Cetero Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Lipid and Diabetes Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic and Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick C. Smith Clinic</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriCities Medical Research</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>November 4, 2010</last_update_submitted>
  <last_update_submitted_qc>November 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Neil M Cowen, PhD/Chief Scientific Officer</name_title>
    <organization>Essentialis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

